Skip to main content
. Author manuscript; available in PMC: 2010 Dec 11.
Published in final edited form as: Vaccine. 2009 Oct 29;28(2):352–360. doi: 10.1016/j.vaccine.2009.10.040

Fig. 5.

Fig. 5

Virus neutralization by sera from mice immunized with the gp120JRFL/654-D complex. (A–B) Sera collected after the final immunization with the gp120JRFL/654-D complex and MPL/DDA was serially diluted and tested for neutralizing activity with TZM-bl target cells against viruses expressing different HIV-1 envelope proteins in two different assays described in the Materials and Methods section. (C) Sera from control animals immunized with PBS and MPL/DDA were also tested against the same set of viruses to establish the background neutralization levels. (D) Sera from mice immunized with the gp120JRFL/654-D complex were pre-treated with serum-reactive V3MN peptide, non-reactive V3LAI peptide, or control peptide (40 µg/ml) and tested for the capacity to neutralize SF162. (E) For comparison, neutralization activity of the anti-V3 mAb 447-52D was assessed against viruses expressing envelope proteins of SF162, SS1196.1, 3988.25, MN, HXB-2 and JRFL. The averages and standard deviations are shown, and each experiment was repeated at least twice.